

ISO 5910:2018 (E)

Cardiovascular implants and extracorporeal systems — Cardiac valve repair devices

Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms and definitions
4	Abbreviations
5	Fundamental requirements
5.1	General
5.2	Risk management
6	Device description
6.1	Intended use/Indication for use
6.2	Design inputs
6.2.1	General
6.2.2	Operational specifications
6.2.3	Functional, performance and safety requirements
6.2.3.1	General
6.2.3.2	Implantable device
6.2.3.3	Delivery system (if applicable)
6.2.4	Usability
6.2.5	Packaging, labelling, and sterilization
6.3	Design outputs
6.4	Design transfer (manufacturing verification/validation)
7	Design verification testing and analysis / Design validation
7.1	General requirements
7.2	In vitro assessment
7.2.1	General
7.2.2	Test articles, sample selection, test conditions and reporting requirements
7.2.2.1	Test articles and sample selection
7.2.2.2	Test conditions
7.2.2.3	Reporting requirements
7.2.3	Device material property assessment
7.2.3.1	General
7.2.3.2	Biological safety
7.2.3.3	Material property testing
7.2.4	Functional performance assessment
7.2.5	Device structural performance assessment
7.2.5.1	General
7.2.5.2	Structural component fatigue assessment
7.2.5.3	Device durability assessment
7.2.6	Device corrosion assessment
7.2.7	Delivery system design evaluation requirements
7.2.8	Visibility
7.2.9	Simulated use assessment
7.2.10	Human factors / Usability assessment
7.2.11	Device MRI safety

- 7.2.12 Design specific testing
- 7.3 Preclinical in vivo evaluation
 - 7.3.1 General
 - 7.3.2 Overall requirements
 - 7.3.3 Methods
 - 7.3.4 Test report
- 7.4 Clinical Investigations
 - 7.4.1 General
 - 7.4.2 Study considerations
 - 7.4.2.1 General
 - 7.4.2.2 Direct Visualization Surgical Devices
 - 7.4.2.3 Transcatheter Devices
 - 7.4.3 Study endpoints
 - 7.4.4 Ethical considerations
 - 7.4.5 Distribution of subjects and investigators
 - 7.4.6 Statistical considerations including sample size and duration
 - 7.4.7 Patient selection criteria
 - 7.4.8 Clinical data requirements
 - 7.4.8.1 General
 - 7.4.8.2 Baseline
 - 7.4.8.3 Peri-Procedure Data
 - 7.4.8.4 Follow-Up Data
 - 7.4.9 Clinical investigation analysis and reporting
 - 7.4.10 Post-market clinical follow-up

Annex A (informative) Rationale for the provisions of this document

- A.1 Rationale for risk based approach
- A.2 Rationale for preclinical in vivo evaluation
- A.3 Rationale for design verification and design validation testing
- A.4 Rationale for imaging assessment
- A.5 Rationale for clinical evaluation reporting
- A.6 Rationale for device configuration within labelling and instructions for use
- A.7 Rationale for human factors engineering

Annex B (informative) Examples of heart valve repair devices and delivery systems

- B.1 General
- B.2 Examples of heart valve repair devices
- B.3 Examples of heart valve repair device delivery systems

Annex C (normative) Packaging

- C.1 Requirements
- C.2 Principle
- C.3 Containers
 - C.3.1 Unit container(s)
 - C.3.2 Outer container

Annex D (normative) Product labels, instructions for use, and training

- D.1 Requirements
 - D.1.1 General
 - D.1.2 Unit-container label
 - D.1.3 Outer-container label
 - D.1.4 Instructions for use
 - D.1.5 Labels for medical records
- D.2 Training for physicians and support staff

Annex E (normative) Sterilization

- E.1 General

Annex F (informative) Heart valve repair system characteristics

- F.1 General
- F.2 Characteristics of heart valve repair device
- F.3 Characteristics of delivery system
- F.4 Chemical treatments, surface modifications, or coatings
- F.5 Implant procedure

F.6	Accessories
Annex G	(informative) Heart valve repair system hazards, associated failure modes and evaluation methods
G.1	General
G.2	Hazards, failure modes, and evaluation methods
G.3	Failure modes/ hazards related to the delivery system
G.4	Additional generic failure modes and causes
Annex H	(informative) In vitro test guidelines for paediatric devices
H.1	Introduction and paediatric definitions
H.2	Pulsatile flow test conditions
H.3	FEA/life analysis conditions
Annex I	(informative) Examples and definitions of some physical and material properties of heart valve repair device components
I.1	General
I.2	Bulk physical properties
I.3	Surface physical properties
I.3.1	General
I.4	Mechanical and chemical engineering properties
I.5	Nitinol properties
I.5.1	General
Annex J	(informative) Examples of standards applicable to testing of materials and components of heart valve repair devices
J.1	Metals
J.1.1	Specifications for materials for metal implants
J.1.2	Tensile test with extensometer to failure
J.1.3	Poisson's ratio
J.1.4	Durability crack initiation and endurance limit; S-N curves
J.1.5	Fatigue crack growth rate; crack growth velocity
J.1.6	Hardness
J.1.7	Microstructure
J.1.8	Thermal expansion
J.1.9	Fracture toughness
J.1.10	Fatigue life
J.1.11	Corrosion
J.2	Polymers
J.2.1	Viscosimetry
J.2.2	Melt flow index
J.2.3	Determination of breaking strength under static load
J.2.4	Tensile test with extensometer to failure (if possible)
J.2.5	Poisson's ratio
J.2.6	Determination of dynamic mechanical properties
J.2.7	Resistance to surface wear
J.2.8	Resistance to scratch
J.2.9	Flexural properties; determination of breaking strength under dynamic bending load
J.2.10	Fatigue crack initiation and endurance limit; S-N curves
J.2.11	Fatigue crack growth rate
J.2.12	Determination of compressive properties
J.2.13	Specification of surgical implants made from high-density silicone elastomer
J.2.14	Density
J.2.15	Liquid diffusivity (porosity and permeability; water absorption)
J.2.16	Hardness
J.2.17	Wear resistance
J.2.18	Creep
J.2.19	Fracture toughness
J.2.20	Hydraulic expansion
J.3	Ceramics and carbons
J.3.1	Physical and chemical properties
J.3.2	Fatigue rate
J.3.3	Hardness
J.3.4	Thermal expansion

- J.3.5 Fracture toughness
- J.4 Plastic materials
- J.4.1 Possible adaptation of tensile properties
- J.5 Textiles
- J.5.1 Determination of tear-out resistance
- J.5.2 Determination of water absorption
- J.5.3 Determination of breaking strength under static load
- J.5.4 MRI compatibility

Annex K (informative) Considerations for device material properties undergoing alterations post implantation

Annex L (informative) Corrosion assessment

- L.1 Rationale
- L.2 Introduction
- L.3 Pitting corrosion
- L.4 Crevice corrosion
- L.5 Galvanic corrosion
- L.6 Corrosion fatigue
- L.7 Fretting (wear) and fretting corrosion
- L.8 Post-fatigue corrosion evaluation

Annex M (informative) Guidelines for in vitro evaluation of functional performance of the repair

- M.1 General
- M.2 Steady back-flow leakage testing
 - M.2.1 Measuring equipment accuracy
 - M.2.2 Test apparatus requirements
 - M.2.3 Test procedure
 - M.2.4 Test report
- M.3 Pulsatile-flow testing
 - M.3.1 Measuring equipment accuracy
 - M.3.2 Test apparatus requirements
 - M.3.3 Test procedure
 - M.3.4 Test report

Annex N (informative) Durability testing

- N.1 General
- N.2 Measurement equipment accuracy
- N.3 Test parameters
- N.4 Results evaluation
- N.5 Real time wear testing
- N.6 Dynamic Failure Mode
- N.7 Report requirements

Annex O (informative) Fatigue assessment

- O.1 General
- O.2 Stress/strain analysis of structural components of the heart valve repair device under simulated in vivo conditions
- O.3 Fatigue characterization
 - O.3.1 General
 - O.3.2 Stress/life (S/N) characterization
 - O.3.3 Strain/life (ϵ/N) characterization
 - O.3.4 Fatigue crack growth (da/dN) characterization
 - O.3.5 Component testing
- O.4 Fatigue lifetime assessment
 - O.4.1 General
 - O.4.2 Stress-life (S/N) assessment
 - O.4.3 Strain-life (ϵ/N) assessment
 - O.4.4 Damage tolerance analysis (DTA)
 - O.4.5 Component demonstration assessment
 - O.4.6 Test to Failure
 - O.4.7 Post Fatigue Evaluation

Annex P (informative) Preclinical in vivo evaluation

- P.1 General
- P.2 Definitions
- P.3 Evaluations
 - P.3.1 Haemodynamic performance
 - P.3.2 Ease of use
 - P.3.3 Device migration or embolisation
 - P.3.4 Interference with or damage to adjacent anatomical structures
 - P.3.5 Haemolysis
 - P.3.6 Thromboembolic events
 - P.3.7 Calcification/mineralization
 - P.3.8 Pannus formation/tissue ingrowth
 - P.3.9 Structural and non-structural dysfunction
 - P.3.10 Assessment of device and non-device related pathology

Annex Q (normative) Adverse event classification during clinical investigation

- Q.1 General
- Q.2 Evaluation
- Q.3 Data collection requirements
- Q.4 Adverse events
- Q.5 Adverse device effects
- Q.6 Device deficiencies
- Q.7 Classification of causal relationships
- Q.8 Classification of adverse events
 - Q.8.1 General
 - Q.8.2 Examples of adverse events
- Q.9 Comparison to surgical valve repair
- Q.10 Outcome Severity Rankings
- Q.11 Follow up of SAEs

Annex R (informative) Imaging protocol

- R.1 General
- R.2 Echocardiographic studies
- R.3 Data collected
- R.4 Computed Tomography (CT) studies
- R.5 Cardiac Magnetic Resonance (CMR)

Annex S (informative) Clinical investigation endpoints for valve repair devices: Suggestions for endpoints and their timing

- S.1 General
- S.2 Single endpoints
 - S.2.1 General
 - S.2.2 Safety
 - S.2.3 Performance and Effectiveness
 - S.2.4 Heart failure hospitalization definition
 - S.2.5 Composite endpoints
 - S.2.6 Timing of endpoints

Annex T (informative) Additional device design evaluation requirements

- T.1 General
- T.2 Device migration resistance
- T.3 Implant foreshortening (length to diameter)
- T.4 Crush resistance
- T.5 Recoil (balloon expandable stents)
- T.6 Radial resistive force
- T.7 Chronic Outward Force (COF)
- T.8 Anatomic interactions

Annex U (informative) Guidelines for delivery system design evaluation

- U.1 General
- U.2 Implant interactions with delivery system
- U.3 Loading/ attachment of device to delivery system
- U.4 Ability to access and deploy